The American Diabetes Association – Diabetes and Cardiovascular Disease Interest Group recently named Armando Vergara-Martel, research assistant in the Cardiovascular Research Institute at the School of Medicine, a winner of its Early Career Abstract Award.
The title of Vergara-Martel’s abstract is “Proteomic Analysis of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) – Results and Integrated Predictors of Response.”
The proteomic findings from the MAGMA trial, funded by the National Institutes of Health, were unveiled, offering significant insights for researchers and patients on the effects of spironolactone. The study, currently in preprint and led by Principal Investigator Sanjay Rajagopalan, director of the Cardiovascular Research Institute at CWRU, demonstrated that spironolactone notably slows the progression of atherosclerosis and reduces left ventricular mass. Additionally, it alters proteins linked to pathways involved in inflammation, cytokine activation, and immunity, which was the focus of this abstract.
Last month, Vergara-Martel shared the findings during the American Diabetes Association Scientific Sessions, the premier event for diabetes professionals in North America.